Skip to contentT
TELA Bio, Inc.
T
TELATELA Bio, Inc. Q2 2023 · 10-Q
Revenue$14.49M$14.49M+39.3% vs Q2 2022 Net Income-$10.79M-$10.79MN/M vs Q2 2022 EPS Diluted-$0.46-$0.46N/M vs Q2 2022 Gross Profit$10,201,000+55.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TELA Bio, Inc. · CIK 1561921 · Engraved from SEC EDGAR
Operating Cash Flowderived-$11,264,000N/M Free Cash Flowderived-$11,421,000N/M Margins · derivedGross margin70.4%+7.4 pt vs Q2 2022
Operating margin-71.5%+26.9 pt vs Q2 2022
Net margin-74.4%+48.0 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 10, 2023 · 41 d after period end